Grey Wolf Therapeutics raises $50M in Series B extension for clinical trial expansion and autoimmune disease research.
UK-based Grey Wolf Therapeutics raises $50M in Series B extension, led by ICG's Life Sciences team, with existing investors involved. Funds will support expansion of clinical trial for immuno-oncology candidate GRWD5769, and research efforts into autoimmune disease treatments. The company is focusing on antigen modulation therapies, with lead clinical candidate GRWD5769 being a potent and selective oral ERAP1 inhibitor.
May 23, 2024
3 Articles